Codexis Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $19.3 million, up from $8.6 million year over year
- ➤Q3 net loss narrowed to $8.1 million, or $0.08 per share
- ➤Full-year 2026 revenue guidance reiterated at $72 million-$76 million
- ➤2026 gross-margin estimate increased to the low 70% range
- ➤$60 million Trinity Capital term loan includes $42.5 million debt refinancing
Expert Statements
Alison Moore, President and Chief Executive Officer of Codexis
“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field”
Alison Moore, President and Chief Executive Officer of Codexis
“Last week we presented new data at the TIDES Europe annual meeting showing successful scale-up of the ECO Synthesis® Manufacturing Platform at 100-gram scale with high product quality, and including improved process performance with reduced cycle time.”
Alison Moore, President and Chief Executive Officer of Codexis
“In addition, we significantly strengthened our balance sheet with an equity raise of approximately $25 million in net proceeds, completed in July.”
Alison Moore, President and Chief Executive Officer of Codexis
“This was followed by a $60 million term loan agreement which we closed earlier this month, of which $42.5 million was used to refinance our existing debt.”
Alison Moore, President and Chief Executive Officer of Codexis
“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”
Reports revenue of $19.3 million for the third quarter of 2026, company reiterates full-year revenue guidance
Shared new advances in RNA therapeutic manufacturing at TIDES Europe
Get started
Create a free account to read the full story.